ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., a leading innovator in women's health, has achieved a significant milestone with the European approval of its FemBloc® System, the first non-surgical permanent birth control solution. The system has received Conformité Européene $(CE)$ mark certification under the European Union Medical Device Regulation, marking the first regulatory approval of its kind globally. The FemBloc System, which includes a blended polymer component and a delivery system, can now be marketed across the European Economic Area. Femasys plans to roll out the product commercially in select European countries, beginning with Spain, while also pursuing further country approvals and continuing U.S. trials for FDA approval.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。